Major AI players OpenAI and Anthropic have recently signaled IPO intentions while accelerating their push into healthcare. According to MobiHealthNews, Anthropic confidentially submitted a draft S-1 registration statement to the U.S. Securities and Exchange Commission (SEC) a week ago, planning an initial public offering. Meanwhile, OpenAI CEO Sam Altman told employees that the company expects to go public within the next year, with a potential valuation of up to $1 trillion. Both companies have identified healthcare AI as a key growth area, and their IPO progress could shed light on how AI companies build commercial pathways in highly regulated markets.
In the healthcare sector, both firms are actively embedding AI tools into clinical workflows, life sciences, and payer systems. OpenAI’s GPT series is already being used by multiple hospitals to assist with diagnostics and medical record management, while Anthropic’s Claude models focus on molecular simulation in drug discovery and clinical trial data analysis. These use cases touch key stakeholders such as hospitals, health systems, insurers, clinicians, and pharmaceutical companies. As noted by MobiHealthNews, the IPOs will provide a clearer picture of how these AI companies generate revenue in the highly regulated healthcare market—for example, by selling API access directly to medical institutions or offering customized solutions.
